Beta Bionics

Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.

Beta Bionics headquartered in United States, North America, operates in the Biotechnology, Medical Device, Diabetes sector. The company focuses on Biotechnology and has secured $28.2B in funding across 96 round(s). With a team of 101-250 employees, Beta Bionics is actively contributing to advancements in Biotechnology. Their latest funding round, Series D - Beta Bionics, raised $100.0M. Discover more about their projects, partnerships, and impact on our platform.